CAR T-Cell therapies in lymphoma: current landscape, ongoing investigations, and future directions

• 作者: J.Erika Haydu Jeremy S.Abramson
• 来源期刊: 癌症转移与治疗（英文版）
• 年，卷（期）: 2021,（5）
• 所属期刊栏目: Review
• 页码范围: 78-91
• 页数: 14页
• 语种: 英文
• DOI: 10.20517/2394-4722.2021.39

摘要

Chimeric antigen receptor (CAR) T-cell therapy has significantly improved outcomes for patients with relapsed/refractory large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma, with multiple FDA-approved CAR T products now commercially available. Ongoing studies seek to move CAR T-cells to earlier lines of therapy and to characterize the efficacy and safety of CAR T-cell approaches in additional lymphoma histologies including relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia. Other areas of active research address CAR T in combination with other lymphoma-directed therapies, and mechanisms of CAR T resistance. This review focuses on the FDA-approved anti-CD19 CAR T products for B-cell lymphomas, management of CAR T-cell-associated toxicities, approaches to bridging therapy, and ongoing clinical trials and future research directions across a broad range of lymphoma histologies.